AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19549707
Drug: CF (cisplatin-5-fluorouracil);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF (cisplatin-5-fluorouracil); cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Trial: 14715393
Drug: Paracetamol 600/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 600/650 mg
Trial: 11887670
Drug: Dental appliance
RxNorm normalized name: Efferdent Anti-Bacterial Dental Appliance Cleanser Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental appliance treatment for headache patients
Trial: 20643762
Drug: Infliximab combined
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab combined with oral CYC
Trial: 20643762
Drug: Other agents
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other agents including biological agents
Trial: 12946761
Drug: Intracorporeal injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracorporeal injection
Trial: 8899091
Drug: Low-dose rINF-beta
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rINF-beta ser (6 x 10(6) U/dose, three times a week for 6 months)
Trial: 8899091
Drug: High-dose rINF-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rINF-beta ser (30 x 10(6) U/dose, three times a week for 6 months)
Trial: 8899091
Drug: Both low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both low-dose and high-dose rINF-beta ser
Trial: 25148243
Drug: Atomoxetine (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (20-50 mg BID)
Trial: 2180557
Drug: Allopurinol mouthwash
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol mouthwash (20 mg)
Trial: 26060991
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging interviews (administered by human interviewers)
Trial: 26060991
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging interviews (administered by automated systems)
Trial: 26060991
Drug: Voice interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice interviews (administered by human interviewers)
Trial: 26060991
Drug: Voice interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice interviews (administered by automated systems)
Trial: 19111849
Drug: IM aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IM aripiprazole 10 mg
Trial: 19111849
Drug: IM aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IM aripiprazole (5 mg, 10 mg, or 15 mg)
Trial: 17014022
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (amitriptyline and fluoxetine)
Trial: 11090839
Drug: CT-1 antibody
RxNorm normalized name: CT-1
DrugBank: Cardiotrophin 1 (DB18399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-1 antibody
Trial: 11090839
Drug: Ischemic preconditioning
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ischemic preconditioning (PC) with CT-1 antibody
Trial: 9281254
Drug: CMF-chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF-chemotherapy
Trial: 8193733
Drug: Isradipine, 2.5
RxNorm normalized name: Isradipine, 2.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine, 2.5 mg twice daily
Trial: 29508153
Drug: Ivabradine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine + Beta-Blockers
Trial: 29508153
Drug: Beta-Blockers Uptitration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Blockers Uptitration
Trial: 27248464
Drug: SP loaded
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP loaded nanostructured lipid carrier gel (SP-NLC)
Trial: 27248464
Drug: SP loaded
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP loaded alcoholic gel (SP-ALC)
Trial: 11713152
Drug: Oral oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxygen delivery (45 patients)
Trial: 24603565
Drug: No prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prescription
Trial: 24603565
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription (recontact)
Trial: 24603565
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription (post‐dated)
Trial: 24603565
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription (collection)
Trial: 24603565
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription (patient led)
Trial: 23759464
Drug: Assertive specialized
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive specialized treatment
Trial: 21243757
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g bid for 3 months before PESA-ICSI)
Trial: 18440327
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) - single bolus of 60,000 IU administered within 3 hours of PCI
Trial: 16832317
Drug: Methylphenidate (0.94
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.94 +/- 0.02 mg/kg/day = 33.06 +/- 1.40 mg/day)
Trial: 12948399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alpha‐2b (3 MU tiw) and ribavirin (1000‐1200 mg/day)
Trial: 12948399
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy (1000‐1200 mg/day)
Trial: 12948399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon and ribavirin
Trial: 12948399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon ribavirin
Trial: 11049919
Drug: High-flow sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-flow sevoflurane anesthesia (6-10 L/min)
Trial: 11049919
Drug: Low-flow isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-flow isoflurane anesthesia (1 L/min)
Trial: 1530165
Drug: Thiopental with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental with fentanyl (n = 18, fentanyl concentration 1.27 +/- 0.5 ng/mL)
Trial: 3911613
Drug: Liquid dimeticon
RxNorm normalized name: dimethicone Medicated Liquid Soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid dimeticon preparation (480 mg over 24 hours)
Trial: 31621671
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone
Trial: 26362826
Drug: Caucasian whortleberry
RxNorm normalized name: whortleberry substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caucasian whortleberry (1 g/day) for 90 days
Trial: 26362826
Drug: Cinnamon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (1 g/day) for 90 days
Trial: 25168404
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid (10 mL/kg IV 0.9% sodium chloride) with no expectation of medication (Group A)
Trial: 25168404
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid (10 mL/kg IV 0.9% sodium chloride) with expectation of medication (Group B)
Trial: 23257008
Drug: Tetrandrine tablets
DrugBank: Tetrandrine (DB14066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrandrine tablets (100 mg bid) and matrine injection (150 mg qd)
Trial: 23257008
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-inflammatory, cough-relieving, and anti-asthmatic treatment only)
Trial: 23257008
Drug: Tetrandrine tablets
DrugBank: Tetrandrine (DB14066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrandrine tablets combined with matrine injection
Trial: 11783199
Drug: Step respiration
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step respiration exercise (SRE) combined with Chinese drug therapy (CDT)
Trial: 11783199
Drug: Chinese drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drug therapy (CDT)
Trial: 7860833
Drug: Signal detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signal detection model applied to Japanese listeners' /r/-/l/ labeling behavior
Trial: 2045865
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-3 (daily 4-hour intravenous infusion for 28 days at doses of 30, 60, 125, 250, 500, 750, and 1,000 micrograms/m2/d)
Trial: 6941447
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose and two doses of intravenous metronidazole (500 mg/100 ml)
Trial: 6941447
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous metronidazole (500 mg/100 ml) with placebo (100 ml normal saline)
Trial: 6941447
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml normal saline) for both doses
Trial: 23857339
Drug: Satisfaction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satisfaction with treatment
Trial: 19957797
Drug: Heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treatment group (n = 37)
Trial: 19957797
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment group (n = 42)
Trial: 17520105
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of low-dose atorvastatin (5 mg/day) and fenofibrate (160 mg/day)
Trial: 17520105
Drug: Fenofibrate (160-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160-200 mg/day)
Trial: 15339323
Drug: Topical 0.1
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1 n hydrochloric acid
Trial: 11336714
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg rectal misoprostol in 5 cm(3) of saline
Trial: 6393724
Drug: High-dose betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose betamethasone for 4-5 days
Trial: 30674279
Drug: Previous experiences
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous experiences of pain medication
Trial: 30674279
Drug: Understanding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Understanding of pain medication
Trial: 28834103
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich plasma (PRP) weekly for 6 weeks
Trial: 28834103
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (compression and dressing) for 6 weeks
Trial: 22551551
Drug: LR17 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LR17 treatment (early or late)
Trial: 19663922
Drug: Glucose (BD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (BD Glucose Tablets)
Trial: 10597985
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single high dose every 4 months)
Trial: 8565034
Drug: Mepyramine-theophylline-acetate (MTA)
RxNorm normalized name: ambroxol-theophylline-7-acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepyramine-theophylline-acetate (MTA) 8 mg/kg per day by mouth in three divided doses for 7 days
Trial: 8565034
Drug: Placebo 50
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50 microL/kg per day in three divided doses for 7 days
Trial: 31406997
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with 500 mg/kg resveratrol (HT+Res)
Trial: 29315807
Drug: Religion prime
RxNorm normalized name: Ficus religiosa leafy twig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religion prime administered to atheists
Trial: 24625704
Drug: 1-Hz rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-Hz rTMS over the right dorsolateral prefrontal cortex (intensity of 110% of the threshold; 3000 stimuli per protocol; 10 daily sessions) combined with partial sleep deprivation (PSD applied once per week)
Trial: 23171380
Drug: Rhythm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm and music-based therapy program
Trial: 9973914
Drug: iodixanol (Visipaque)
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iodixanol (Visipaque) 270 mg I/ml
Trial: 9973914
Drug: iopamidol (Iopamiron)
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iopamidol (Iopamiron) 300 mg I/ml
Trial: 1689084
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of endogenous opioids
Trial: 1689084
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of endogenous opioids
Trial: 7028529
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (about 75 mg daily)
Trial: 24519844
Drug: Subcutaneous drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drainage (10 Fr drain placed subcutaneously connected to low pressure aspiration reservoir)
Trial: 24519844
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous drainage (control group)
Trial: 24519844
Drug: Subcutaneous drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drainage
Trial: 24519844
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous drainage
Trial: 16217662
Drug: 0.7% dexamethasone‐cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% dexamethasone‐cyclodextrin eye drop solution applied once daily
Trial: 8651235
Drug: Self-reported drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drug injection behaviors
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (single-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (single-vessel disease)
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (double-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (double-vessel disease)
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (triple-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (triple-vessel disease)
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ejection fraction ≥ 0.50, single-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (ejection fraction ≥ 0.50, single-vessel disease)
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ejection fraction ≥ 0.50, double-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (ejection fraction ≥ 0.50, double-vessel disease)
Trial: 6137292
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ejection fraction ≥ 0.50, triple-vessel disease)
Trial: 6137292
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (ejection fraction ≥ 0.50, triple-vessel disease)
Trial: 6137292
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (initially assigned)
Trial: 30947751
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg iron dextran (Cosmofer)
Trial: 30947751
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg iron sucrose (Venofer)
Trial: 30947751
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg iron isomaltoside (Monofer)
Trial: 30947751
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg iron isomaltoside (Monofer)
Trial: 30947751
Drug: All iron
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All iron preparations
Trial: 29135863
Drug: Bone-Anchored Implants
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-Anchored Implants (BAI)
Trial: 20825805
Drug: Phenobarbital (PB)
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB) - mean dosage 509 mg
Trial: 20825805
Drug: Lorazepam (LZ)
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam (LZ) - mean dosage 4.2 mg
Trial: 9467701
Drug: Tailored antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored antihypertensive educational intervention
Trial: 29445029
Drug: Pantoprazole (IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin (60 mg/m2 × 2 days per cycle)
Trial: 29445029
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2 × 2 days per cycle) without Pantoprazole
Trial: 29445029
Drug: Pantoprazole (IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin
Trial: 24726032
Drug: Ongoing low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing low molecular weight heparin treatment for cancer-associated thrombosis
Trial: 24726032
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of low molecular weight heparin at six months treatment (current licensed practice)
Trial: 22994901
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg cyproheptadine (5‐HT antagonist)
Trial: 22994901
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg escitalopram (SSRI)
Trial: 14498766
Drug: Atlizumab (anti-IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atlizumab (anti-IL-6 receptor antibody)
Trial: 10875526
Drug: 1,25‐dihydroxy‐cholecalciferol vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25‐dihydroxy‐cholecalciferol vitamin D (0.25 mcg daily) and calcium (500 mg daily) for 9 months
Trial: 9170524
Drug: PFL-therapy (CDDP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFL-therapy (CDDP, 5-FU, and dl-LV)
Trial: 9170524
Drug: FL-therapy (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL-therapy (5-FU and dl-LV)